Scott+Scott Appointed Lead Counsel in Securities Class ActionAgainst Insulet Corporation
NEW YORK — Scott+Scott Attorneys at Law LLP has been appointed Lead Counsel in a securities class action filed against the medical device manufacturer Insulet Corporation. The case filed in the U.S. District Court for the District of Massachusetts alleges that Insulet and its chief executives made material misstatements to investors regarding its automated insulin delivery system called Omnipod.
According to the complaint, Insulet falsely reassured investors that its product was safe while omitting that Omnipod was not meeting applicable safety regulations. When Insulet finally acknowledged the truth about the device and initiated product corrections, the company’s share price declined from roughly $276 per share at the start of the Class Period to $146 per share at the end causing significant financial losses for investors.
The case is: Hu v. Insulet Corporation, et al. No. 1:26-cv-13062 (LTS) (D. Mass.)